

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237

Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|--|
| <p><u>Company</u></p> <ul style="list-style-type: none"> GlaxoSmithKline (mepolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Asthma + Lung UK NARA – The Breathing Charity Pulmonary Hypertension Association UK South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Respiratory Nurse Specialists British Geriatrics Society British Institute of Radiology British Thoracic Society National Heart and Lung Institute Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health and Social Care NHS England | <p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Chest, Heart and Stroke Scotland Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Northern Ireland Chest, Heart and Stroke Association Scottish Medicines Consortium Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Advanz Pharma (aminophylline, ciclesonide) AstraZeneca (budesonide, formoterol, glycopyrronium, roflumilast, symbicort) Aspire Pharma (fluticasone, salmeterol) Aurobindo Pharma – Milpharm (azithromycin)Boehringer Ingelheim (ipratropium, olodaterol, salbutamol, tiotropium) |

Provisional stakeholder list for the evaluation of mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237

Issue date: April 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 4

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|------------------------|--|
| | <ul style="list-style-type: none"> • Chiesi (beclometasone, fostair, glycopyrronium) • Cipla EU (beclometasone, fluticasone, formoterol, ipratropium, salbutamol, salmeterol) • Ennogen (aminophylline, theophylline) • Genus Pharmaceuticals (beclometasone, fluticasone, formoterol, salmeterol, tiotropium) • Genesis Pharmaceuticals (fluticasone, salmeterol) • Glenmark Pharmaceuticals (beclometasone, salmeterol) • GlaxoSmithKline (fluticasone, seretide, salbutamol, salmeterol, umecclidinium, vilanterol) • Glenmark Pharmaceuticals (tiotropium) • Hameln (aminophylline) • Lupin Healthcare (beclometasone, formoterol) • Mylan (budesonide, salbutamol, salmeterol, tiotropium) • Napp Pharmaceuticals (fluticasone, formoterol) • Novartis (formoterol, glycopyrronium, indacaterol, mometasone) • Organon Pharma (mometasone) • Orion Pharma (beclometasone, budesonide, fluticasone, formoterol, salbutamol) • Pfizer (azithromycin) • Pinewood Healthcare (salbutamol) • Sandoz (azithromycin, fluticasone, salmeterol) • Sanofi (dupilumab) • Orion Pharma (formoterol, salmeterol) • Teva UK (aminophylline, beclometasone, budesonide, formoterol, salbutamol, tiotropium) • UCB (aminophylline) • Wockhardt UK (budesonide, formoterol) |

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|------------------------|---|
| | <ul style="list-style-type: none"> • Zentiva (acclidinium, budesonide, ciclesonide, fluticasone, formoterol, salmeterol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • Cochrane Airways Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Provisional stakeholder list for the evaluation of mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237

Issue date: April 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 3 of 4

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.